Proteomics International Laboratories (ASX:PIQ) may face delays in executing its direct-to-consumer strategy in commercializing its diagnostic tests for diabetes, endometriosis, and esophageal cancer, according to a Tuesday note from Euroz Hartleys.
The company has reaffirmed its plan for the US launch in the first half of 2025 of its lead diagnostic test PromarkerD for detecting diabetic kidney disease, adding that it remains on track for an Australian launch of the test in the first quarter of 2025.
Euroz Hartleys believes that the commercialization could take longer than expected, citing potential execution risks with the direct-to-consumer pathway.
Euroz Hartleys notes that the partners in place in other territories have only covered the pre-launch of PIQ's tests in smaller markets.
The firm maintained a hold rating and price target of AU$0.72 on Proteomics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.